LifeLink Ventures
VC Fund
Barcelona, Spain
LifeLink Ventures is an investment company through which private investors have direct access to exclusive life sciences investments. We look for urgently needed therapies developed by the most driven entrepreneurs and connect them with our network of investors. We believe in the deployment of capital in alignment with a powerful cause –improvement in global health.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries LifeLink Ventures invests in
Stages LifeLink Ventures invests in
Countries LifeLink Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Francisca Peixoto
|
|||
Investment Focus
Industry
- Biotechnology 5 (71%)
- Health Care 4 (57%)
- Therapeutics 4 (57%)
- Medical 2 (29%)
- Genetics 2 (29%)
Stage
- Series A 3 (43%)
- Seed 2 (29%)
- Series B 1 (14%)
Country
- United States 3 (43%)
- Switzerland 1 (14%)
- United Kingdom 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Francisca Peixoto
Founder & Investment Manager
|
Founder & Investment Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Crossbow Therapeutics
|
Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M / Series B / Mar 18, 2026 | |
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M / Series A / May 08, 2025 | |
Arda Therapeutics
|
Arda Therapeutics is a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Their approach starts by using single-cell data to identify pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.Arda wasfounded in 2021 in the San Francisco Bay Area, CA. | $43M / Series A / Oct 01, 2024 | |
Ochre Bio
|
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M / Series A / Oct 10, 2022 | |
|
Ochre Bio
|
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | Series A / Dec 10, 2021 | |
Chameleon Biosciences
|
Chameleon is changing the way they treat genetic diseases using gene therapy to deliver corrective genes using multiple systemic dose administrations.Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are savinglives, but there's still a long way to go. At Chameleon, their goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires. They are committed to every child and family who suffers from a genetic disorder. Their mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own. | $11.1M / Seed / Mar 25, 2021 | |
|
Calyxha Biotechnologies
|
Calyxha is developing novel therapies targeting tissue degeneration that is the fundamental underlying cause of major human diseases. | $1.1M / Seed / Feb 28, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does LifeLink Ventures invest in?
LifeLink Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact LifeLink Ventures?
Public channels for LifeLink Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LifeLink Ventures?
The team at LifeLink Ventures includes Francisca Peixoto (Founder & Investment Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
